{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T23:30:50Z","timestamp":1778110250444,"version":"3.51.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T00:00:00Z","timestamp":1632528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T00:00:00Z","timestamp":1632528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Vet Res"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Pimobendan is a widely used medication for the treatment of dogs with congestive heart failure (CHF) and preclinical degenerative mitral valve disease (DMVD) with cardiomegaly. The benefit of a treatment in dogs with preclinical DMVD but without cardiomegaly has not yet been elucidated. Some positive effects concerning life quality and a decrease in cardiac biomarkers could be verified. This study aimed to further investigate these results using a placebo-controlled double-blinded crossover design. Out of a total of 15 dogs, eight were allocated to sequence-group AB, in which dogs received pimobendan (A) during the first treatment period and placebo (B) during the second period. Accordingly, sequence-group BA was treated first with placebo followed by pimobendan. Each treatment period lasted six months and included a baseline investigation and follow-ups after 90 and 180\u2009days. The investigations included a questionnaire completed by the owners, echocardiographic examination, and measurements of NT-proBNP, cTnI and lactate before and after a standardised submaximal exercise test.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>NT-proBNP values decreased significantly during the treatment period with pimobendan, and the post-exercise increase was attenuated at day 180. No significant treatment effects could be verified for cTnI and lactate, neither pre- nor post-exercise. Left ventricular size decreased under treatment, whereas no significant changes in left atrial size were detected. The owners described their dogs under treatment with pimobendan as being more active at day 90 (11\/15) and day 180 (12\/15). Those animals treated with placebo were described as being more active at day 90 (2\/15) and day 180 (5\/15).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Pimobendan had reducing effects on the concentrations of pre- and post-exercise cardiac biomarkers and the size of the left ventricle in dogs with DMVD ACVIM B1. Exercise testing in addition to an assessment of cardiac biomarkers might improve the decision when to initiate pimobendan treatment in dogs with DMVD.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12917-021-03014-5","type":"journal-article","created":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T16:02:25Z","timestamp":1632585745000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The effect of treatment with pimobendan in dogs with preclinical mitral valve disease \u2013 a placebo-controlled double-blinded crossover study"],"prefix":"10.1186","volume":"17","author":[{"given":"Stephanie","family":"Klein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingo","family":"Nolte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katja","family":"Rumstedt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximiliane","family":"Sehn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan Friedemann","family":"Raue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franziska","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia Sophie","family":"Treese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Beyerbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan-Peter","family":"Bach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,25]]},"reference":[{"issue":"4","key":"3014_CR1","doi-asserted-by":"publisher","first-page":"249","DOI":"10.5326\/0420249","volume":"42","author":"CW Lombard","year":"2006","unstructured":"Lombard CW, J\u00f6ns O, Bussadori CM. Clinical efficacy of pimobendan versus benazepril for the treatment of acquired atrioventricular valvular disease in dogs. J Am Anim Hosp Assoc. 2006;42(4):249\u201361. https:\/\/doi.org\/10.5326\/0420249.","journal-title":"J Am Anim Hosp Assoc"},{"issue":"5","key":"3014_CR2","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1111\/j.1939-1676.2008.0150.x","volume":"22","author":"J H\u00e4ggstr\u00f6m","year":"2008","unstructured":"H\u00e4ggstr\u00f6m J, Boswood A, O'Grady M, J\u00f6ns O, Smith S, Swift S, et al. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study. J Vet Intern Med. 2008;22(5):1124\u201335. https:\/\/doi.org\/10.1111\/j.1939-1676.2008.0150.x.","journal-title":"J Vet Intern Med"},{"issue":"6","key":"3014_CR3","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1111\/j.1939-1676.2011.00800.x","volume":"25","author":"S Suzuki","year":"2011","unstructured":"Suzuki S, Fukushima R, Ishikawa T, Hamabe L, Aytemiz D, Huai-Che H, et al. The effect of pimobendan on left atrial pressure in dogs with mitral valve regurgitation. J Vet Intern Med. 2011;25(6):1328\u201333. https:\/\/doi.org\/10.1111\/j.1939-1676.2011.00800.x.","journal-title":"J Vet Intern Med"},{"issue":"6","key":"3014_CR4","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1111\/jvim.14586","volume":"30","author":"A Boswood","year":"2016","unstructured":"Boswood A, H\u00e4ggstr\u00f6m J, Gordon SG, Wess G, Stepien RL, Oyama MA, et al. Effect of pimobendan in dogs with preclinical myxomatous mitral valve disease and cardiomegaly: the EPIC study-a randomized clinical trial. J Vet Intern Med. 2016;30(6):1765\u201379. https:\/\/doi.org\/10.1111\/jvim.14586.","journal-title":"J Vet Intern Med"},{"issue":"3","key":"3014_CR5","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1111\/jvim.15488","volume":"33","author":"BW Keene","year":"2019","unstructured":"Keene BW, Atkins CE, Bonagura JD, Fox PR, H\u00e4ggstr\u00f6m J, Fuentes VL, et al. ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs. J Vet Intern Med. 2019;33(3):1127\u201340. https:\/\/doi.org\/10.1111\/jvim.15488.","journal-title":"J Vet Intern Med"},{"issue":"1","key":"3014_CR6","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1385\/CT:5:1:043","volume":"5","author":"R Tissier","year":"2005","unstructured":"Tissier R, Chetboul V, Moraillon R, Nicolle A, Carlos C, Enriquez B, et al. Increased mitral valve regurgitation and myocardial hypertrophy in two dogs with long-term pimobendan therapy. Cardiovasc Toxicol. 2005;5(1):43\u201351. https:\/\/doi.org\/10.1385\/CT:5:1:043.","journal-title":"Cardiovasc Toxicol"},{"issue":"1","key":"3014_CR7","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jvc.2011.11.005","volume":"14","author":"V Chetboul","year":"2012","unstructured":"Chetboul V, Tissier R. Echocardiographic assessment of canine degenerative mitral valve disease. J Vet Cardiol. 2012;14(1):127\u201348. https:\/\/doi.org\/10.1016\/j.jvc.2011.11.005.","journal-title":"J Vet Cardiol"},{"issue":"1","key":"3014_CR8","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s12917-019-1980-z","volume":"15","author":"N Iwanuk","year":"2019","unstructured":"Iwanuk N, Nolte I, Wall L, Sehn M, Raue J, Pilgram A, et al. Effect of Pimobendan on NT-proBNP and c troponin I before and after a submaximal exercise test in dogs with preclinical mitral valve disease without cardiomegaly - a randomised, double-blinded trial. BMC Vet Res. 2019;15(1):237. https:\/\/doi.org\/10.1186\/s12917-019-1980-z.","journal-title":"BMC Vet Res"},{"issue":"10","key":"3014_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0223164","volume":"14","author":"N Iwanuk","year":"2019","unstructured":"Iwanuk N, Wall L, Nolte I, Raue J, Rumstedt K, Pilgram A, et al. Effect of pimobendan on physical fitness, lactate and echocardiographic parameters in dogs with preclinical mitral valve disease without cardiomegaly. PLoS One. 2019;14(10):e0223164. https:\/\/doi.org\/10.1371\/journal.pone.0223164.","journal-title":"PLoS One"},{"issue":"9","key":"3014_CR10","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.2460\/javma.244.9.1075","volume":"244","author":"MA Giuffrida","year":"2014","unstructured":"Giuffrida MA. Type II error and statistical power in reports of small animal clinical trials. J Am Vet Med Assoc. 2014;244(9):1075\u201380. https:\/\/doi.org\/10.2460\/javma.244.9.1075.","journal-title":"J Am Vet Med Assoc"},{"issue":"5","key":"3014_CR11","doi-asserted-by":"publisher","first-page":"547","DOI":"10.2460\/javma.249.5.547","volume":"249","author":"MA Giuffrida","year":"2016","unstructured":"Giuffrida MA. Defining the primary research question in veterinary clinical studies. J Am Vet Med Assoc. 2016;249(5):547\u201351. https:\/\/doi.org\/10.2460\/javma.249.5.547.","journal-title":"J Am Vet Med Assoc"},{"key":"3014_CR12","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jvc.2019.12.002","volume":"27","author":"M Borgarelli","year":"2020","unstructured":"Borgarelli M, Ferasin L, Lamb K, Bussadori C, Chiavegato D, D'Agnolo G, et al. DELay of appearance of sYmptoms of canine degenerative mitral valve disease treated with spironolactone and benazepril: the DELAY study. J Vet Cardiol. 2020;27:34\u201353. https:\/\/doi.org\/10.1016\/j.jvc.2019.12.002.","journal-title":"J Vet Cardiol"},{"issue":"Suppl 1","key":"3014_CR13","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/1751-0147-44-S1-S127","volume":"98","author":"AK Ersb\u00f8ll","year":"2003","unstructured":"Ersb\u00f8ll AK, Ersb\u00f8ll BK. Epidemiological studies based on small sample sizes - a statistician's point of view. Acta Vet Scand Suppl. 2003;98(Suppl 1):127\u201340. https:\/\/doi.org\/10.1186\/1751-0147-44-S1-S127.","journal-title":"Acta Vet Scand Suppl"},{"issue":"1","key":"3014_CR14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1365-2125.1979.tb05903.x","volume":"8","author":"M Hills","year":"1979","unstructured":"Hills M, Armitage P. The two-period cross-over clinical trial. Br J Clin Pharmacol. 1979;8(1):7\u201320. https:\/\/doi.org\/10.1111\/j.1365-2125.1979.tb05903.x.","journal-title":"Br J Clin Pharmacol"},{"key":"3014_CR15","first-page":"7","volume":"1033","author":"P Armitage","year":"1998","unstructured":"Armitage P, Colton T. Encyclopedia of biostatistics: J. Wiley. 1998;1033:7.","journal-title":"Wiley"},{"key":"3014_CR16","doi-asserted-by":"publisher","unstructured":"Jones B, Kenward MG. Design and analysis of cross-over trials: CRC press; 2014, DOI: https:\/\/doi.org\/10.1201\/b17537.","DOI":"10.1201\/b17537"},{"issue":"6","key":"3014_CR17","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/j.1740-8261.2002.tb01051.x","volume":"43","author":"K Hansson","year":"2002","unstructured":"Hansson K, H\u00e4ggstr\u00f6m J, Kvart C, Lord P. Left atrial to aortic root indices using two-dimensional and M-mode echocardiography in cavalier king Charles spaniels with and without left atrial enlargement. Vet Radiol Ultrasound. 2002;43(6):568\u201375. https:\/\/doi.org\/10.1111\/j.1740-8261.2002.tb01051.x.","journal-title":"Vet Radiol Ultrasound"},{"issue":"3","key":"3014_CR18","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/j.1939-1676.2004.tb02551.x","volume":"18","author":"CC Cornell","year":"2004","unstructured":"Cornell CC, Kittleson MD, Della Torre P, H\u00e4ggstr\u00f6m J, Lombard CW, Pedersen HD, et al. Allometric scaling of M-mode cardiac measurements in normal adult dogs. J Vet Intern Med. 2004;18(3):311\u201321. https:\/\/doi.org\/10.1111\/j.1939-1676.2004.tb02551.x.","journal-title":"J Vet Intern Med"},{"issue":"6","key":"3014_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0199023","volume":"13","author":"L Wall","year":"2018","unstructured":"Wall L, Mohr A, Ripoli FL, Schulze N, Penter CD, Hungerbuehler S, et al. Clinical use of submaximal treadmill exercise testing and assessments of cardiac biomarkers NT-proBNP and cTnI in dogs with presymptomatic mitral regurgitation. PLoS One. 2018;13(6):e0199023. https:\/\/doi.org\/10.1371\/journal.pone.0199023.","journal-title":"PLoS One"},{"key":"3014_CR20","unstructured":"Feng WW, Ding D, editors. SAS@ application in 2\u00d7 2 crossover clinical trial. Proceedings of the Pharmaceutical SAS Users Group Conference; 2004."},{"issue":"6","key":"3014_CR21","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1111\/j.1939-1676.2009.0390.x","volume":"23","author":"KJ Atkinson","year":"2009","unstructured":"Atkinson KJ, Fine DM, Thombs LA, Gorelick JJ, Durham HE. Evaluation of pimobendan and N-terminal probrain natriuretic peptide in the treatment of pulmonary hypertension secondary to degenerative mitral valve disease in dogs. J Vet Intern Med. 2009;23(6):1190\u20136. https:\/\/doi.org\/10.1111\/j.1939-1676.2009.0390.x.","journal-title":"J Vet Intern Med"},{"issue":"3","key":"3014_CR22","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.pcad.2017.11.004","volume":"60","author":"M B\u00e4ck","year":"2017","unstructured":"B\u00e4ck M, Pizarro R, Clavel MA. Biomarkers in mitral regurgitation. Prog Cardiovasc Dis. 2017;60(3):334\u201341. https:\/\/doi.org\/10.1016\/j.pcad.2017.11.004.","journal-title":"Prog Cardiovasc Dis"},{"issue":"5 Suppl","key":"3014_CR23","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.1016\/j.cardfail.2005.04.019","volume":"11","author":"C Hall","year":"2005","unstructured":"Hall C. NT-ProBNP: the mechanism behind the marker. J Card Fail. 2005;11(5 Suppl):S81\u20133. https:\/\/doi.org\/10.1016\/j.cardfail.2005.04.019.","journal-title":"J Card Fail"},{"issue":"Suppl 2","key":"3014_CR24","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1097\/00005344-198906142-00002","volume":"14","author":"JC van Meel","year":"1989","unstructured":"van Meel JC, Diederen W. Hemodynamic profile of the cardiotonic agent pimobendan. J Cardiovasc Pharmacol. 1989;14(Suppl 2):S1\u20136. https:\/\/doi.org\/10.1097\/00005344-198906142-00002.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"Suppl 1","key":"3014_CR25","doi-asserted-by":"publisher","first-page":"S93","DOI":"10.1016\/j.jvc.2009.03.003","volume":"11","author":"HB Kellihan","year":"2009","unstructured":"Kellihan HB, Oyama MA, Reynolds CA, Stepien RL. Weekly variability of plasma and serum NT-proBNP measurements in normal dogs. J Vet Cardiol. 2009;11(Suppl 1):S93\u20137. https:\/\/doi.org\/10.1016\/j.jvc.2009.03.003.","journal-title":"J Vet Cardiol"},{"issue":"4","key":"3014_CR26","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1292\/jvms.69.373","volume":"69","author":"N Kanno","year":"2007","unstructured":"Kanno N, Kuse H, Kawasaki M, Hara A, Kano R, Sasaki Y. Effects of pimobendan for mitral valve regurgitation in dogs. J Vet Med Sci. 2007;69(4):373\u20137. https:\/\/doi.org\/10.1292\/jvms.69.373.","journal-title":"J Vet Med Sci"},{"issue":"2","key":"3014_CR27","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/j.1748-5827.2009.00889.x","volume":"51","author":"W Moonarmart","year":"2010","unstructured":"Moonarmart W, Boswood A, Luis Fuentes V, Brodbelt D, Souttar K, Elliott J. N-terminal pro B-type natriuretic peptide and left ventricular diameter independently predict mortality in dogs with mitral valve disease. J Small Anim Pract. 2010;51(2):84\u201396. https:\/\/doi.org\/10.1111\/j.1748-5827.2009.00889.x.","journal-title":"J Small Anim Pract"},{"issue":"6","key":"3014_CR28","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1111\/j.1939-1676.2012.01026.x","volume":"26","author":"NJ Summerfield","year":"2012","unstructured":"Summerfield NJ, Boswood A, O'Grady MR, Gordon SG, Dukes-McEwan J, Oyama MA, et al. Efficacy of pimobendan in the prevention of congestive heart failure or sudden death in Doberman pinschers with preclinical dilated cardiomyopathy (the PROTECT study). J Vet Intern Med. 2012;26(6):1337\u201349. https:\/\/doi.org\/10.1111\/j.1939-1676.2012.01026.x.","journal-title":"J Vet Intern Med"},{"issue":"1","key":"3014_CR29","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/j.1939-1676.2009.0407.x","volume":"24","author":"KR Mu\u00f1ana","year":"2010","unstructured":"Mu\u00f1ana KR, Zhang D, Patterson EE. Placebo effect in canine epilepsy trials. J Vet Intern Med. 2010;24(1):166\u201370. https:\/\/doi.org\/10.1111\/j.1939-1676.2009.0407.x.","journal-title":"J Vet Intern Med"},{"issue":"1","key":"3014_CR30","doi-asserted-by":"publisher","first-page":"104","DOI":"10.2460\/javma.233.1.104","volume":"233","author":"MA Oyama","year":"2008","unstructured":"Oyama MA, Rush JE, O'Sullivan ML, Williams RM, Rozanski EA, Petrie JP, et al. Perceptions and priorities of owners of dogs with heart disease regarding quality versus quantity of life for their pets. J Am Vet Med Assoc. 2008;233(1):104\u20138. https:\/\/doi.org\/10.2460\/javma.233.1.104.","journal-title":"J Am Vet Med Assoc"},{"issue":"2","key":"3014_CR31","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/j.1939-1676.2008.0239.x","volume":"23","author":"M Ouellet","year":"2009","unstructured":"Ouellet M, B\u00e9langer MC, Difruscia R, Beauchamp G. Effect of pimobendan on echocardiographic values in dogs with asymptomatic mitral valve disease. J Vet Intern Med. 2009;23(2):258\u201363. https:\/\/doi.org\/10.1111\/j.1939-1676.2008.0239.x.","journal-title":"J Vet Intern Med"},{"issue":"6","key":"3014_CR32","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1111\/j.1939-1676.2004.tb02629.x","volume":"18","author":"MA Oyama","year":"2004","unstructured":"Oyama MA, Sisson DD. Cardiac troponin-I concentration in dogs with cardiac disease. J Vet Intern Med. 2004;18(6):831\u20139. https:\/\/doi.org\/10.1111\/j.1939-1676.2004.tb02629.x.","journal-title":"J Vet Intern Med"},{"issue":"4","key":"3014_CR33","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1111\/j.1939-1676.2007.tb03016.x","volume":"21","author":"V Chetboul","year":"2007","unstructured":"Chetboul V, Lefebvre HP, Sampedrano CC, Gouni V, Saponaro V, Serres F, et al. Comparative adverse cardiac effects of pimobendan and benazepril monotherapy in dogs with mild degenerative mitral valve disease: a prospective, controlled, blinded, and randomized study. J Vet Intern Med. 2007;21(4):742\u201353. https:\/\/doi.org\/10.1111\/j.1939-1676.2007.tb03016.x.","journal-title":"J Vet Intern Med"},{"issue":"10","key":"3014_CR34","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.2460\/javma.230.10.1486","volume":"230","author":"EC McKenzie","year":"2007","unstructured":"McKenzie EC, Jose-Cunilleras E, Hinchcliff KW, Holbrook TC, Royer C, Payton ME, et al. Serum chemistry alterations in Alaskan sled dogs during five successive days of prolonged endurance exercise. J Am Vet Med Assoc. 2007;230(10):1486\u201392. https:\/\/doi.org\/10.2460\/javma.230.10.1486.","journal-title":"J Am Vet Med Assoc"},{"issue":"3","key":"3014_CR35","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jacc.2010.03.037","volume":"56","author":"R Shave","year":"2010","unstructured":"Shave R, Baggish A, George K, Wood M, Scharhag J, Whyte G, et al. Exercise-induced cardiac troponin elevation: evidence, mechanisms, and implications. J Am Coll Cardiol. 2010;56(3):169\u201376. https:\/\/doi.org\/10.1016\/j.jacc.2010.03.037.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"3014_CR36","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1111\/j.1939-1676.2010.0594.x","volume":"24","author":"JJ Wakshlag","year":"2010","unstructured":"Wakshlag JJ, Kraus MS, Gelzer AR, Downey RL, Vacchani P. The influence of high-intensity moderate duration exercise on cardiac troponin I and C-reactive protein in sled dogs. J Vet Intern Med. 2010;24(6):1388\u201392. https:\/\/doi.org\/10.1111\/j.1939-1676.2010.0594.x.","journal-title":"J Vet Intern Med"},{"issue":"2","key":"3014_CR37","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/j.1939-1676.2012.00894.x","volume":"26","author":"MJ Hezzell","year":"2012","unstructured":"Hezzell MJ, Boswood A, Chang YM, Moonarmart W, Souttar K, Elliott J. The combined prognostic potential of serum high-sensitivity cardiac troponin I and N-terminal pro-B-type natriuretic peptide concentrations in dogs with degenerative mitral valve disease. J Vet Intern Med. 2012;26(2):302\u201311. https:\/\/doi.org\/10.1111\/j.1939-1676.2012.00894.x.","journal-title":"J Vet Intern Med"},{"issue":"1","key":"3014_CR38","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/j.1939-1676.2011.00860.x","volume":"26","author":"M Borgarelli","year":"2012","unstructured":"Borgarelli M, Crosara S, Lamb K, Savarino P, La Rosa G, Tarducci A, et al. Survival characteristics and prognostic variables of dogs with preclinical chronic degenerative mitral valve disease attributable to myxomatous degeneration. J Vet Intern Med. 2012;26(1):69\u201375. https:\/\/doi.org\/10.1111\/j.1939-1676.2011.00860.x.","journal-title":"J Vet Intern Med"},{"issue":"1","key":"3014_CR39","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/j.1939-1676.2007.0008.x","volume":"22","author":"M Borgarelli","year":"2008","unstructured":"Borgarelli M, Savarino P, Crosara S, Santilli RA, Chiavegato D, Poggi M, et al. Survival characteristics and prognostic variables of dogs with mitral regurgitation attributable to myxomatous valve disease. J Vet Intern Med. 2008;22(1):120\u20138. https:\/\/doi.org\/10.1111\/j.1939-1676.2007.0008.x.","journal-title":"J Vet Intern Med"},{"issue":"1","key":"3014_CR40","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0002-9149(00)00827-4","volume":"86","author":"LW Gibbons","year":"2000","unstructured":"Gibbons LW, Mitchell TL, Wei M, Blair SN, Cooper KH. Maximal exercise test as a predictor of risk for mortality from coronary heart disease in asymptomatic men. Am J Cardiol. 2000;86(1):53\u20138. https:\/\/doi.org\/10.1016\/S0002-9149(00)00827-4.","journal-title":"Am J Cardiol"},{"issue":"9","key":"3014_CR41","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.cjca.2014.03.013","volume":"30","author":"C Henri","year":"2014","unstructured":"Henri C, Pi\u00e9rard LA, Lancellotti P, Mongeon F-P, Pibarot P, Basmadjian AJ. Exercise testing and stress imaging in Valvular heart disease. Can J Cardiol. 2014;30(9):1012\u201326. https:\/\/doi.org\/10.1016\/j.cjca.2014.03.013.","journal-title":"Can J Cardiol"},{"issue":"4","key":"3014_CR42","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1046\/j.1365-2796.2000.00736.x","volume":"248","author":"M Kato","year":"2000","unstructured":"Kato M, Kinugawa T, Ogino K, Endo A, Osaki S, Igawa O, et al. Augmented response in plasma brain natriuretic peptide to dynamic exercise in patients with left ventricular dysfunction and congestive heart failure. J Intern Med. 2000;248(4):309\u201315. https:\/\/doi.org\/10.1046\/j.1365-2796.2000.00736.x.","journal-title":"J Intern Med"},{"issue":"11","key":"3014_CR43","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1093\/eurjhf\/hfs114","volume":"14","author":"J Magne","year":"2012","unstructured":"Magne J, Mahjoub H, Pibarot P, Pirlet C, Pierard LA, Lancellotti P. Prognostic importance of exercise brain natriuretic peptide in asymptomatic degenerative mitral regurgitation. Eur J Heart Fail. 2012;14(11):1293\u2013302. https:\/\/doi.org\/10.1093\/eurjhf\/hfs114.","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"3014_CR44","doi-asserted-by":"publisher","first-page":"797","DOI":"10.14740\/jocmr2680w","volume":"8","author":"SK Sinha","year":"2016","unstructured":"Sinha SK, Garg S, Thakur R, Krishna V, Singh K, Sachan M, et al. Prognostic importance of exercise brain natriuretic peptide in asymptomatic chronic organic severe mitral regurgitation: an observational study. J Clin Med Res. 2016;8(11):797\u2013804. https:\/\/doi.org\/10.14740\/jocmr2680w.","journal-title":"J Clin Med Res"},{"key":"3014_CR45","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jvc.2019.11.001","volume":"26","author":"M Rishniw","year":"2019","unstructured":"Rishniw M, Caivano D, Dickson D, Vatne L, Harris J, Matos JN. Two-dimensional echocardiographic left- atrial-to-aortic ratio in healthy adult dogs: a reexamination of reference intervals. J Vet Cardiol. 2019;26:29\u201338. https:\/\/doi.org\/10.1016\/j.jvc.2019.11.001.","journal-title":"J Vet Cardiol"},{"issue":"24","key":"3014_CR46","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1016\/j.jacc.2009.07.046","volume":"54","author":"E Picano","year":"2009","unstructured":"Picano E, Pibarot P, Lancellotti P, Monin JL, Bonow RO. The emerging role of exercise testing and stress echocardiography in valvular heart disease. J Am Coll Cardiol. 2009;54(24):2251\u201360. https:\/\/doi.org\/10.1016\/j.jacc.2009.07.046.","journal-title":"J Am Coll Cardiol"}],"container-title":["BMC Veterinary Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-021-03014-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12917-021-03014-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-021-03014-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T16:06:05Z","timestamp":1632585965000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcvetres.biomedcentral.com\/articles\/10.1186\/s12917-021-03014-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,25]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3014"],"URL":"https:\/\/doi.org\/10.1186\/s12917-021-03014-5","relation":{},"ISSN":["1746-6148"],"issn-type":[{"value":"1746-6148","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,25]]},"assertion":[{"value":"31 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by an ethical review committee (Lower Saxony State Office for Consumer Protection and Food Safety (LAVES), 33.9\u201342502-05-14A484) and was carried out in compliance with the ARRIVE guidelines. All methods were carried out in accordance with the relevant guidelines and regulations. Written informed consent was obtained from each owner of the participating dogs.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"310"}}